Morgan Stanley Concert Pharmaceuticals, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.34 - $5.84 $1.64 Million - $2.21 Million	-378,037 Reduced 39.0%	591,380 $3.45 Million
Q3 2022 Nov 14, 2022	BUY	$4.27 - $7.2 $1.1 Million - $1.85 Million	257,208 Added 36.11%	969,417 $6.5 Million
Q2 2022 Oct 27, 2022	BUY	$2.8 - $6.36 $1.8 Million - $4.1 Million	644,102 Added 945.72%	712,209 $3 Million
Q2 2022 Aug 15, 2022	BUY	$2.8 - $6.36 $1.8 Million - $4.1 Million	644,102 Added 945.72%	712,209 $3 Million
Q1 2022 Oct 27, 2022	SELL	$2.73 - $3.94 $1.76 Million - $2.54 Million	-644,102 Reduced 90.44%	68,107 $229,000
Q1 2022 May 13, 2022	SELL	$2.73 - $3.94 $575,017 - $829,878	-210,629 Reduced 75.57%	68,107 $229,000
Q4 2021 Feb 14, 2022	BUY	$2.69 - $4.22 $214,836 - $337,030	79,865 Added 40.16%	278,736 $878,000
Q3 2021 Nov 15, 2021	BUY	$3.17 - $4.15 $630,421 - $825,314	198,871 New	198,871 $651,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.